근거 중심의 패혈증 치료에 대한 최신 지견

키워드

참고문헌 (32)

1. Houck PM, "Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community- acquired pneumonia", Arch Intern Med, 164, pp.637~644 (2004)
2. Ibrahim EH, "The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting", Chest, 118, pp.146~155 (2000)
3. Garnacho-Montero J, "Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis", Crit Care Med, 31, pp.2742~2751 (2003)
4. Jenkins I, "Evidence-based sepsis therapy: a hospitalist perspective", J Hosp Med, 1, pp.285~295 (2006)
5. Nguyen HB, "Emergency Department Sepsis Education Program and Strategies to Improve Survival (ED-SEPSIS) Working Group:Severe sepsis and septic shock: review of the literature and emergency department management guidelines", Ann Emerg Med, 48, pp.28~54 (2006)
6. Rivers E, "Early Goal-Directed Therapy Collaborative Group:Early goal-directed therapy in the treatment of severe sepsis and septic shock", N Engl J Med, 345, pp.1368~1377 (2001)
7. Dellinger RP, "International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine:Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 200", Crit Care Med, 36, pp.296~327 (2008)
8. The Acute Respiratory Distress Syndrome Network, "Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome", N Engl J Med, 342, pp.1301~138 (2000)
9. Malmberg K, "Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study", Circulation, 99, pp.2626~2632 (1999)
10. Whitcomb BW, "Impact of admission hyperglycemia on hospital mortality in various intensive care unit populations", Crit Care Med, 33, pp.2772~2777 (2005)
11. Van den Berghe G, "Intensive insulin therapy in critically ill patients", N Engl J Med, 345, pp.1359~1367 (2001)
12. Van den Berghe G, "Intensive insulin therapy in the medical ICU", N Engl J Med, 354, pp.449~461 (2006)
13. Lefering R, "Steroid controversy in sepsis and septic shock: a meta-analysis", Crit Care Med, 23, pp.1294~1303 (1995)
14. Annane D, "Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock", JAMA, 288, pp.862~871 (2002)
15. Bollaert PE, "Reversal of late septic shock with supraphysiologic doses of hydrocortisone", Crit Care Med, 26, pp.645~650 (1998)
16. Annane D, "Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis", BMJ, 329, pp.480~488 (2004)
17. Sessler CN, "Management of severe sepsis and septic shock", Curr Opin Crit Care, 20, pp.354~363 (2004)
18. Annane D, "Septic shock", Lancet, 365, pp.63~78 (2005)
19. Sprung CL, "CORTICUS Study Group:Hydrocortisone therapy for patients with septic shock", N Engl J Med, 358, pp.111~124 (2008)
20. O'Brien JM, "Sepsis", Am J Med, 120, pp.1012~1022 (2007)
21. Bernard GR, "Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis", N Engl J Med, 344, pp.699~709 (2001)
22. Vincent JL, "Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment", Crit Care Med, 33, pp.2266~2277 (2005)
23. Abraham E, "Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group:Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death", N Engl J Med, 353, pp.1332~1341 (2005)
24. in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation, "Crit Care Med", 2007, 1457~1463
25. Nadel S, "Researching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group: Drotrecogin alfa (activated) in children with severe sepsis: a multicenter phase III randomized controlled trial", Lancet, 369, pp.836~843 (2007)
26. Werdan K, "Immunoglobulin in sepsis: therapeutic use of immunoglobulins", Sepsis, 3, pp.239~245 (1999)
27. Jolles S, "Clinical use of intravenous immunoglobulin", Clin Exp Immunol, 142, pp.1~11 (2005)
28. Pildal J, "Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review", Clin Infect Dis, 39, pp.38~46 (2004)
29. Turgeon AF, "Meta- analysis:intravenous immunoglobulin in critically ill adult patients with sepsis", Ann Intern Med, 146, pp.193~203 (2007)
30. Kreymann KG, "Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock", Crit Care Med, 35, pp.2677~2685 (2007)
31. Laupland KB, "Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis", Crit Care Med, 35, pp.2686~2692 (2007)
32. Werdan K, "Score-Based Immunoglobulin Therapy of Sepsis (SBITS) Study Group:Score- based immunglobulin G therapy of patients with sepsis: The SBITS study", Crit Care Med, 35, pp.2693~2701 (2007)

관련 논문AI추천